European Journal of Dermatology
MENUA case of delgocitinib-indued anti-LAD-1 IgG-positive, anti-BP180 NC16A IgG-negative bullous pemphigoid in a patient with atopic dermatitis Volume 31, numéro 4, July-August 2021
Illustrations
Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan
- DOI : 10.1684/ejd.2021.4105
- Page(s) : 578-9
- Année de parution : 2021
Janus kinase (JAK) is now recognized to play a role in various immunological processes. There are four types of JAKs: JAK1, JAK2, JAK3, and tyrosine kinase 2. JAK inhibitors have been utilized as therapeutic agents for inflammatory diseases including skin diseases (e.g. atopic dermatitis [AD], psoriasis vulgaris, and vitiligo) [1]. The main adverse cutaneous event is local skin infections including herpes simplex/zoster and molluscum contagiosum, but eruptive squamous cell carcinoma and severe drug [...]